1
|
Molica S, Rossi M, Allsup D. Epcoritamab in B-cell malignancies: current status and prospects. Expert Opin Biol Ther 2024; 24:1-5. [PMID: 38343083 DOI: 10.1080/14712598.2024.2310148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2023] [Accepted: 01/22/2024] [Indexed: 02/15/2024]
Affiliation(s)
- Stefano Molica
- Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull University NHS Trust, Hull, UK
| | - Marco Rossi
- Department Haematology, Azienda Ospedaliera-Universitaria "Renato Dulbecco", Catanzaro, Italy
- Università Magna Graecia, Catanzaro, Italy
| | - David Allsup
- Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull University NHS Trust, Hull, UK
- Centre of Biomedicine, Hull York Medical School, University of Hull, Hull, UK
| |
Collapse
|
2
|
Jin S, Liu Y, Zhang Y, Zhou F, You L, Zhang J. Bispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting. Ther Adv Chronic Dis 2023; 14:20406223231215701. [PMID: 38058395 PMCID: PMC10697048 DOI: 10.1177/20406223231215701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2023] [Accepted: 11/03/2023] [Indexed: 12/08/2023] Open
Affiliation(s)
- Shenhe Jin
- Department of Hematology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China
| | - Yi Liu
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China
| | - Ye Zhang
- Department of Hematology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China
| | - Fengping Zhou
- Department of Hematology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China
| | - Liangshun You
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou 310003, People’s Republic of China
- Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, Zhejiang, People’s Republic of China
- Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, Zhejiang, People’s Republic of China
- Zhejiang University Cancer Center, Hangzhou, Zhejiang, People’s Republic of China
| | - Jin Zhang
- Department of Hematology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People’s Republic of China
| |
Collapse
|
3
|
Tavarozzi R, Zacchi G, Pietrasanta D, Catania G, Castellino A, Monaco F, Gandolfo C, Rivela P, Sofia A, Schiena N, Bertassello C, Limberti G, Zallio F, Zanni M, Ladetto M. Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice. Cancers (Basel) 2023; 15:5397. [PMID: 38001657 PMCID: PMC10670523 DOI: 10.3390/cancers15225397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2023] [Revised: 11/03/2023] [Accepted: 11/09/2023] [Indexed: 11/26/2023] Open
Abstract
We are currently witnessing a dramatic shift in our approach to the treatment of B-cell non-Hodgkin lymphoma (B-NHL). In the evolving clinical landscape, novel treatments for this clinically heterogeneous disease span a wide range of interventions, encompassing targeted agents, cell therapy approaches, and novel monoclonal antibodies (NMABs). Among these, the latter are likely to exert the most profound impact due to their distinctive high efficacy and versatile applicability. NMABs represent a heterogeneous group of agents, including naked antibodies, immunotoxins, and T-cell-engaging molecules. In recent times, several NMABs have either gained regulatory approval or are on the verge of introduction into clinical practice, addressing multiple therapeutic indications and treatment regimens. Their anticipated impact is expected to be broad, initially in the context of relapsed/refractory (R/R) disease and subsequently extending to early treatment lines. The scope of this review is to provide a comprehensive overview of the biological characteristics, clinical properties, efficacy, and toxicity profiles of NMABs that have recently been introduced or are nearing integration into clinical practice.
Collapse
Affiliation(s)
- Rita Tavarozzi
- Department of Translational Medicine, University of Eastern Piedmont, 28100 Novara, Italy; (P.R.); (C.B.)
- Division of Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy; (G.Z.); (C.G.); (N.S.)
| | - Giulia Zacchi
- Division of Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy; (G.Z.); (C.G.); (N.S.)
| | - Daniela Pietrasanta
- Division of Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy; (G.Z.); (C.G.); (N.S.)
| | - Gioacchino Catania
- Division of Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy; (G.Z.); (C.G.); (N.S.)
| | - Alessia Castellino
- Department of Hematology, Santa Croce e Carle Hospital, 12100 Cuneo, Italy
| | - Federico Monaco
- Division of Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy; (G.Z.); (C.G.); (N.S.)
| | - Carolina Gandolfo
- Division of Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy; (G.Z.); (C.G.); (N.S.)
| | - Paolo Rivela
- Department of Translational Medicine, University of Eastern Piedmont, 28100 Novara, Italy; (P.R.); (C.B.)
- Division of Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy; (G.Z.); (C.G.); (N.S.)
| | - Antonella Sofia
- Division of Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy; (G.Z.); (C.G.); (N.S.)
| | - Noemi Schiena
- Division of Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy; (G.Z.); (C.G.); (N.S.)
| | - Claudia Bertassello
- Department of Translational Medicine, University of Eastern Piedmont, 28100 Novara, Italy; (P.R.); (C.B.)
- Division of Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy; (G.Z.); (C.G.); (N.S.)
| | - Giulia Limberti
- Department of Translational Medicine, University of Eastern Piedmont, 28100 Novara, Italy; (P.R.); (C.B.)
- Division of Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy; (G.Z.); (C.G.); (N.S.)
| | - Francesco Zallio
- Division of Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy; (G.Z.); (C.G.); (N.S.)
| | - Manuela Zanni
- Division of Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy; (G.Z.); (C.G.); (N.S.)
| | - Marco Ladetto
- Department of Translational Medicine, University of Eastern Piedmont, 28100 Novara, Italy; (P.R.); (C.B.)
- Division of Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy; (G.Z.); (C.G.); (N.S.)
| |
Collapse
|